Phase II trial of Lenvatinib in patients with metastatic or recurrent thymic carcinoma;REMORA trial (NCCH1508,REMORA trial)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 05 Mar 2018
At a glance
- Drugs Lenvatinib (Primary)
- Indications Malignant thymoma
- Focus Therapeutic Use
- Acronyms REMORA trial
- 01 Mar 2018 Status changed from recruiting to active, no longer recruiting.
- 11 Sep 2017 Status changed from suspended to recruiting.
- 20 Jun 2017 Status changed from recruiting to suspended.